Illumina (NASDAQ:ILMN) Director Keith Meister Sells 283,269 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 283,269 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $199.61, for a total value of $56,543,325.09. Following the completion of the sale, the director directly owned 2,089,425 shares in the company, valued at approximately $417,070,124.25. This represents a 11.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $193.72 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The business’s fifty day moving average price is $180.63 and its two-hundred day moving average price is $148.77. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $207.00. The stock has a market capitalization of $29.25 billion, a price-to-earnings ratio of 36.14, a price-to-earnings-growth ratio of 2.81 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same period last year, the business earned $1.19 earnings per share. The business’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts predict that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Baxter Bros Inc. bought a new stake in Illumina during the 2nd quarter worth about $295,000. Uniting Wealth Partners LLC bought a new position in shares of Illumina in the second quarter worth about $352,000. Old West Investment Management LLC bought a new position in shares of Illumina in the second quarter worth about $22,472,000. Diamond Hill Capital Management LLC Investment Advisor acquired a new position in shares of Illumina during the second quarter worth approximately $53,038,000. Finally, Global Retirement Partners LLC acquired a new position in shares of Illumina during the second quarter worth approximately $324,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of recent analyst reports. Evercore restated an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. TD Cowen raised their price objective on shares of Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a report on Friday, July 31st. Piper Sandler reiterated an “overweight” rating and issued a $225.00 target price (up from $200.00) on shares of Illumina in a research note on Monday. Royal Bank Of Canada boosted their target price on Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Finally, Deutsche Bank Aktiengesellschaft downgraded Illumina to a “hold” rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $188.40.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Zacks upgraded Illumina from “hold” to “strong buy,” citing favorable momentum characteristics. The company has also benefited from strong clinical momentum and continued leadership in genomic sequencing. Why Illumina Is a Strong Momentum Stock
• Positive Sentiment: Piper Sandler reiterated an “overweight” rating, while TD Cowen maintained its “hold” rating. The mixed views indicate some analysts remain constructive on Illumina’s longer-term opportunity despite near-term concerns. Piper Sandler Reiterates Overweight Rating
• Neutral Sentiment: Illumina’s recent earnings showed revenue growth and an EPS beat, but investors remain focused on the sustainability of demand and whether growth can justify the stock’s elevated valuation following its strong 52-week advance.
• Negative Sentiment: Director Keith A. Meister sold approximately 741,000 Illumina shares across August 4 and 5 for a combined value of about $148.2 million, reducing his holdings by roughly 28% over the two transactions. Although he still owns more than 2 million shares, the large sales may weigh on investor sentiment. Illumina Insider Trading Filing
• Negative Sentiment: Bank of America Securities reiterated a “sell” rating and a $140 price target, arguing that a one-time consumables benefit is masking weak underlying demand. The target is substantially below recent trading levels, reinforcing concerns about near-term operating momentum. Bank of America Maintains Sell Rating on Illumina

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.